Pediatric Rheumatology Association of Japan recommendation for vaccination in pediatric rheumatic diseases.
Pediatric Rheumatology Association of Japan has developed evidence-based guideline of vaccination in pediatric rheumatic diseases (PRDs) as a part of Guideline of Vaccination for Pediatric Immunocompromised Hosts. Available articles on vaccination in both adult rheumatic diseases and PRDs were analyzed. Non-live vaccines are generally safe and effective in patients with PRDs on corticosteroid, immunosuppressant, and/or biologics, although efficacy may be attenuated under high dose of the drugs. On the other hand, efficacy and safety of live-attenuated vaccine for the patients on such medication have not been established. Thus, live-attenuated vaccines should be withheld and, if indicated, may be considered as a clinical trial under the approval by Institutional Review Board. All patients with PRDs anticipating treatment with immunosuppressants or biologics should be screened for infection of hepatitis B and C and tuberculosis before the commencement of medication. Varicella vaccine should be considered in sensitive patients ideally 3 weeks or longer before the commencement of immunosuppressants, corticosteroids, or biologics. Bacille Calmette-Guérin should be withheld at least for 6 months after birth, if their mothers have received anti-tumor necrosis factor-α antibodies during the second or third trimester of pregnancy.
Department of Pediatrics, Hokkaido University Graduate School of Medicine , Sapporo , Japan.
Ichiro
I
Kobayashi
Masaaki
M
Mori
Ken-Ichi
K
Yamaguchi
Shuichi
S
Ito
Naomi
N
Iwata
Kenji
K
Masunaga
Naoki
N
Shimojo
Tadashi
T
Ariga
Kenji
K
Okada
Shuji
S
Takei
D002648:Child; D006801:Humans; D016867:Immunocompromised Host; D007564:Japan; D010372:Pediatrics; D012216:Rheumatic Diseases; D012219:Rheumatology; D014611:Vaccination; D014613:Vaccines, Attenuated
D014613:Vaccines, Attenuated
Immunosuppression; Pediatric; Rheumatic disease; Vaccine